BR112018074299A2 - composições farmacêuticas compreendendo eteplirsen - Google Patents
composições farmacêuticas compreendendo eteplirsenInfo
- Publication number
- BR112018074299A2 BR112018074299A2 BR112018074299-6A BR112018074299A BR112018074299A2 BR 112018074299 A2 BR112018074299 A2 BR 112018074299A2 BR 112018074299 A BR112018074299 A BR 112018074299A BR 112018074299 A2 BR112018074299 A2 BR 112018074299A2
- Authority
- BR
- Brazil
- Prior art keywords
- eteplirsen
- pharmaceutical compositions
- subject
- administering
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
Abstract
são fornecidas aqui composições farmacêuticas compreendendo eteplirsen. também são fornecidos aqui métodos de tratamento de uma doença muscular em um indivíduo com necessidade do mesmo, compreendendo administrar ao indivíduo uma composição farmacêutica da divulgação.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662340947P | 2016-05-24 | 2016-05-24 | |
US62/340,947 | 2016-05-24 | ||
US201662429160P | 2016-12-02 | 2016-12-02 | |
US62/429,160 | 2016-12-02 | ||
PCT/US2017/034265 WO2017213854A1 (en) | 2016-05-24 | 2017-05-24 | Pharmaceutical composition comprising eteplirsen |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018074299A2 true BR112018074299A2 (pt) | 2019-03-12 |
Family
ID=59093599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018074299-6A BR112018074299A2 (pt) | 2016-05-24 | 2017-05-24 | composições farmacêuticas compreendendo eteplirsen |
Country Status (15)
Country | Link |
---|---|
US (1) | US20190275072A1 (pt) |
EP (1) | EP3463390A1 (pt) |
JP (1) | JP2019516730A (pt) |
KR (1) | KR20190009343A (pt) |
CN (1) | CN109562123A (pt) |
AU (1) | AU2017278699A1 (pt) |
BR (1) | BR112018074299A2 (pt) |
CA (1) | CA3024178A1 (pt) |
CO (1) | CO2018013828A2 (pt) |
IL (1) | IL263040A (pt) |
MA (1) | MA45158A (pt) |
MX (1) | MX2018014129A (pt) |
SG (1) | SG11201809494VA (pt) |
TW (1) | TW201805002A (pt) |
WO (1) | WO2017213854A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
JP2021526796A (ja) * | 2018-06-13 | 2021-10-11 | サレプタ セラピューティクス, インコーポレイテッド | 筋ジストロフィーに対するエクソンスキッピングオリゴマー |
EP4219717A3 (en) * | 2018-06-13 | 2023-12-20 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
WO2019241470A2 (en) * | 2018-06-14 | 2019-12-19 | Sarepta Therapeutics, Inc. | Exon skipping oligomers and oligomer conjugates for muscular dystrophy |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
ATE81872T1 (de) | 1985-03-15 | 1992-11-15 | James Summerton | Stereoregulare polynukleotiden bindende polymere. |
US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
DE68914843T2 (de) | 1988-09-01 | 1994-11-10 | Risoe Forskningscenter | Peptid-synthese und fester träger zur verwendung dabei. |
HUE028632T2 (en) | 2004-06-28 | 2016-12-28 | Univ Western Australia | To skip an antisense oligonucleotide exon and use it for procedures |
US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
KR101617472B1 (ko) | 2007-11-15 | 2016-05-02 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 모르폴리노 올리고머의 합성 방법 |
US8076476B2 (en) | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
US8299206B2 (en) | 2007-11-15 | 2012-10-30 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
PT2623507T (pt) | 2010-09-30 | 2016-12-23 | Nippon Shinyaku Co Ltd | Derivado de ácido morfolino-nucleico |
JP6496549B2 (ja) | 2011-11-30 | 2019-04-03 | サレプタ セラピューティクス, インコーポレイテッド | 脊髄性筋萎縮症における誘発されたエクソン包含 |
CN103933549A (zh) * | 2013-01-17 | 2014-07-23 | 刘海俊 | 一种新的血管抑素滴眼剂及其制备方法 |
US9506058B2 (en) * | 2013-03-15 | 2016-11-29 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
-
2017
- 2017-05-24 MA MA045158A patent/MA45158A/fr unknown
- 2017-05-24 KR KR1020187036635A patent/KR20190009343A/ko not_active Application Discontinuation
- 2017-05-24 AU AU2017278699A patent/AU2017278699A1/en not_active Abandoned
- 2017-05-24 TW TW106117190A patent/TW201805002A/zh unknown
- 2017-05-24 SG SG11201809494VA patent/SG11201809494VA/en unknown
- 2017-05-24 MX MX2018014129A patent/MX2018014129A/es unknown
- 2017-05-24 CA CA3024178A patent/CA3024178A1/en not_active Abandoned
- 2017-05-24 BR BR112018074299-6A patent/BR112018074299A2/pt not_active Application Discontinuation
- 2017-05-24 US US16/302,484 patent/US20190275072A1/en not_active Abandoned
- 2017-05-24 EP EP17731957.1A patent/EP3463390A1/en not_active Withdrawn
- 2017-05-24 JP JP2018560674A patent/JP2019516730A/ja active Pending
- 2017-05-24 WO PCT/US2017/034265 patent/WO2017213854A1/en unknown
- 2017-05-24 CN CN201780030581.5A patent/CN109562123A/zh active Pending
-
2018
- 2018-11-15 IL IL263040A patent/IL263040A/en unknown
- 2018-12-19 CO CONC2018/0013828A patent/CO2018013828A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2017278699A1 (en) | 2018-11-15 |
EP3463390A1 (en) | 2019-04-10 |
SG11201809494VA (en) | 2018-12-28 |
IL263040A (en) | 2018-12-31 |
CO2018013828A2 (es) | 2018-12-28 |
US20190275072A1 (en) | 2019-09-12 |
CA3024178A1 (en) | 2017-12-14 |
TW201805002A (zh) | 2018-02-16 |
CN109562123A (zh) | 2019-04-02 |
JP2019516730A (ja) | 2019-06-20 |
WO2017213854A1 (en) | 2017-12-14 |
KR20190009343A (ko) | 2019-01-28 |
MX2018014129A (es) | 2019-04-29 |
MA45158A (fr) | 2019-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021009673A (es) | Moduladores de ror-gamma. | |
MX2022001755A (es) | Compuestos de dinucleotidos ciclicos y metodos de uso. | |
MX2018002990A (es) | Uso de la akkermansia pasteurizada para tratar trastornos metabolicos. | |
BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
BR112017011923A2 (pt) | bactéria modificada para tratar doenças associadas com hiperamonemia | |
BR112017023269A2 (pt) | métodos para tratamento de câncer | |
MX2017004838A (es) | Composiciones de interleucina-15 y usos de estas. | |
PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
SG10201902664RA (en) | Combination therapy for treating cancer | |
PH12018500315A1 (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
WO2015117010A3 (en) | Bag3 as a target for therapy of heart failure | |
BR112016027871A2 (pt) | composição para melhorar a memória, a função de aprendizado e/ou função cognitiva | |
EA201991447A1 (ru) | Снижение вязкости фармацевтических составов | |
BR112017010177A2 (pt) | composição para tratamento de tecido | |
EA201591925A1 (ru) | Терапевтические композиции и их применение | |
MX2017002816A (es) | Derivados de pirazolopiridina y su uso en terapia. | |
MX356755B (es) | Compuestos de tipo fumagilol y metodos para su elaboración y uso. | |
BR112018074299A2 (pt) | composições farmacêuticas compreendendo eteplirsen | |
EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
NO20180002A1 (en) | Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors | |
MX2018005825A (es) | Celulas inmunes modificadas y usos de las mismas. | |
MX2017012596A (es) | Una composicion farmaceutica y el uso de la misma. | |
BR112018000217A2 (pt) | sistemas de distribuição de nanopartículas aperfeiçoados | |
EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
GB201302343D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods for using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |